X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

R&D Focus: 5 things to know about the biopharmaceutical research ecosystem

By Jocelyn Ulrich  |    July 13, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

The latest: What they are saying: Importance of intellectual property protections to combat COVID-19

By Tom Wilbur  |    July 2, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19

By Tom Wilbur  |    June 5, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new treatments and cures for patients. Strong IP protections are...   Read More

IP Explained: Intellectual property system working to combat COVID-19

By Megan Van Etten  |    May 28, 2020
Biopharmaceutical companies are working around the clock to research and develop COVID-19 vaccines and treatments. Intellectual property (IP) has enabled robust research collaboration among...   Read More

What they are saying: Intellectual property protections are critical as we work to defeat COVID-19

By Tom Wilbur  |    May 4, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new breakthrough treatments and cures for patients. Strong IP...   Read More

The continued imperative to protect U.S. innovation worldwide

By Chris Moore  |    April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...   Read More

IP Explained: Four key takeaways from new Bayh-Dole white paper

By Tom Wilbur  |    February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...   Read More

Trump administration must defend and protect U.S. innovation

By Priscilla VanderVeer  |    February 6, 2020
PhRMA recently submitted comments to the Office of the United States Trade Representative (USTR)’s Special 301 Report, calling on the Trump administration to defend American biopharmaceutical...   Read More

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

By Tom Wilbur  |    November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...   Read More

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act

By Tom Wilbur  |    October 9, 2019
In our last IP Explained post, we outlined how the Bayh-Dole Act laid the foundation for effective technology transfer across industries in the United States and helps foster continued medical...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

Subscribe to Email Updates